Plano ng Spruce Biosciences na magsumite ng TA-ERT BLA sa Q4 2026

Sinabi ng Spruce na isinusulong nito ang pagmamanupaktura, pakikipag-ugnayan sa regulasyon, at pagpaplano ng komersyal upang suportahan ang nakaplanong pagsusumite ng BLA para sa TA-ERT sa ika-apat na quarter ng 2026. Ang paghahain ay magiging unang aplikasyon sa regulasyon para sa isang therapy na nagbabago ng sakit sa MPS IIIB, isang kondisyon na walang aprubadong paggamot. Inihayag din ng kumpanya ang pinatibay na cash runway hanggang sa ikalawang kalahati ng 2027 upang masakop ang pagsusumite at potensyal na pag-apruba.

Mahahalagang fact

Na-file: May 13, 2026, 12:05 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Neutral
Kumpanya: SPRBSpruce Biosciences
Asset: tralesinidase alfa
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Long-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened Leadership Team Across Commercial, Clinical Development, and Regulatory Functions to Support BLA Submission and Pre-Launch Readiness Closed Underwritten Public Offering for $69.0 Million in Gross Proceeds, Extending Cash Runway into the Second Half of 2027 and Beyond Anticipated Potential FDA Approval of TA-ERT Entered into Loan and Security Agreement with Avenue Capital for up to $50.0 Million in Term Loans to Strengthen Financial Flexibil

SEC 8-K